Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Exclusion Criteria

• •1. Participants who have received any systemic anti-cancer treatment for thymic epithelial tumor, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment;
• •2. Participants with any unstable systemic disease (including active infection, uncontrolled hypertension), unstable angina pectoris, angina pectoris starting in the last three months, congestive heart failure (\>= NYHA) Grade II), myocardial infarction (6 months before admission), severe arrhythmia requiring drug treatment, liver, kidney or metabolic diseases;
• •3. With activate or suspectable autoimmune disease, or autoimmune paracancer syndrome requiring systemic treatment;
• •4. Participants who are allergic to the test drug or any auxiliary materials;
• •5. Participants with Interstitial lung disease currently;
• •6. Participants with active hepatitis B, hepatitis C or HIV;
• •7. Pregnant or lactating women;
• •8. Participants suffering from nervous system diseases or mental diseases that cannot cooperate;
• •9. Participated in another therapeutic clinical study;
• •10. Other factors that researchers think it is not suitable for enrollment.